Drug details:
Molecular formula: C₁₈H₁₃ClN₂O₂

Standard name: 4-chloro-N-[(E)-(2-hydroxynaphthalen-1-yl)methylideneamino]benzamide

Synonyms:

Benzhydrazide, 4-chloro-N2-(2-hydroxy-1-naphthylmethylene)- 4-Chloro-N'-(2-hydroxy-1-naphthylidene)benzohydrazide 4-chloro-N'-[(2-hydroxy-1-naphthyl)methylene]benzohydrazide 4-chloro-N'-[(1E)-(2-hydroxy-1-naphthyl)methylene]benzohydrazide 4-Chloro-N'-[(E)-(2-hydroxy-1-naphthyl)methylidene]benzohydrazide #

Curated SMILES: O=C(N/N=C/C1=C(O)C=CC2=CC=CC=C21)C1=CC=C(Cl)C=C1

Evidence for compound's anti-virulence activity:

Chlamydia
Related VF: TTSS (Type III secretion system)
Target: Not determined
Drug effect: Inhibits T3SS activity and causes a dose- and growth phase-dependant inhibition of chlamydial RB multiplication: a partial block of entry, an inhibition of the translocation of the TTS effectors IncG and IncA during the early and middle phase, respectively, and a bacterial detachment from the inclusion membrane during the late stage concomitant with an inhibition of terminal differentiation from RBs to infectious EBs.
Max phase: Preclinical (in vitro)
Publication:
Muschiol S, et al., 2006. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc Natl Acad Sci U S A 103(39):14566-71.

Salmonella
Related VF: TTSS (SPI-1 encode); TTSS (SPI-2 encode)
Target: Not determined
Drug effect: Efficiently affected SPI1 and SPI2 activity.
Max phase: Preclinical (in vitro)
Publication:
Negrea A, et al., 2007. Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar typhimurium. Antimicrob Agents Chemother 51(8):2867-76.

Shigella
Related VF: TTSS (Type III secretion system)
Target: MxiH
Drug effect: Inhibits needle assembly.
Max phase: Preclinical (in vitro)
Publication:
Veenendaal AK, et al., 2009. Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton. J Bacteriol 191(2):563-70.